Cargando…

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

INTRODUCTION: BRCA-mutated breast cancer cells lack the DNA-repair mechanism homologous recombination that is required for error-free DNA double-strand break (DSB) repair. Homologous recombination deficiency (HRD) may cause hypersensitivity to DNA DSB-inducing agents, such as bifunctional alkylating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vollebergh, Marieke A, Lips, Esther H, Nederlof, Petra M, Wessels, Lodewyk FA, Wesseling, Jelle, vd Vijver, Marc J, de Vries, Elisabeth GE, van Tinteren, Harm, Jonkers, Jos, Hauptmann, Michael, Rodenhuis, Sjoerd, Linn, Sabine C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076636/ https://www.ncbi.nlm.nih.gov/pubmed/24887359 http://dx.doi.org/10.1186/bcr3655

Ejemplares similares

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
por: Lips, Esther H, et al.
Publicado: (2011)

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
por: Vollebergh, M. A., et al.
Publicado: (2011)

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers
por: Holstege, Henne, et al.
Publicado: (2010)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases
por: Vollebergh, Marieke A., et al.
Publicado: (2014)

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study
por: Gross, Eva, et al.
Publicado: (2016)

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
por: Lips, Esther H., et al.
Publicado: (2015)

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
por: Schouten, Philip C., et al.
Publicado: (2016)

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
por: Lips, Esther H., et al.
Publicado: (2020)

Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation
por: de Jong, Vincent M. T., et al.
Publicado: (2022)

The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives
por: van de Vijver, Marc J
Publicado: (1999)

Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1
por: Ratanaphan, Adisorn, et al.
Publicado: (2014)

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes
por: de Ronde, Jorma J., et al.
Publicado: (2014)

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
por: Holstege, Henne, et al.
Publicado: (2010)

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
por: Bhin, Jinhyuk, et al.
Publicado: (2023)

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations
por: Garcia, Andrew, et al.
Publicado: (2019)

Robust BRCA1‐like classification of copy number profiles of samples repeated across different datasets and platforms
por: Schouten, Philip C., et al.
Publicado: (2015)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
por: Moon, D H, et al.
Publicado: (2013)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Preclinical mouse models for BRCA1-associated breast cancer
por: Drost, R M, et al.
Publicado: (2009)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
por: Olivier, R I, et al.
Publicado: (2004)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
por: Tacconi, Eliana MC, et al.
Publicado: (2017)

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
por: Annunziato, Stefano, et al.
Publicado: (2019)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
por: Cortesi, L., et al.
Publicado: (2023)

Suppression of BRCA1 sensitizes cells to proteasome inhibitors
por: Gu, Y, et al.
Publicado: (2014)

Ovarian Cancer–Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
por: Schouten, Philip C., et al.
Publicado: (2021)

Epistatic Relationships in the BRCA1-BRCA2 Pathway
por: Scully, Ralph
Publicado: (2011)

A model of the BRCA1/BRCA2 network
por: Pujana, MA, et al.
Publicado: (2005)

Molecular Trajectory of BRCA1 and BRCA2 Mutations
por: Hatano, Yuichiro, et al.
Publicado: (2020)

BRCA1 tumor suppression occurs via heterochromatin mediated silencing
por: Zhu, Quan, et al.
Publicado: (2011)

Identifying subgroup markers in heterogeneous populations
por: de Ronde, Jorma J., et al.
Publicado: (2013)

BRCA1 and BRCA2 mutations in Scotland and Northern Ireland
Publicado: (2003)

Clinical significance of large rearrangements in BRCA1 and BRCA2
por: Judkins, Thaddeus, et al.
Publicado: (2012)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis
por: Li, Qianyan, et al.
Publicado: (2021)

Prediction of carrying a BRCA1 or BRCA2 mutation
por: Lee, Kyung-Hun
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uu6sokq191ou3a3g7jmdv5vrea